Current Report Filing (8-k)
January 09 2018 - 12:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest
event reported): January 9, 2018
NEKTAR THERAPEUTICS
(Exact Name of Registrant as Specified
in Charter)
Delaware
|
|
0-24006
|
|
94-3134940
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
455 Mission Bay Boulevard South
San Francisco, California 94158
(Address of Principal Executive Offices
and Zip Code)
Registrant’s telephone number,
including area code: (415) 482-5300
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
|
Item 2.02
|
Results of Operations and Financial Condition.
|
Please
see the disclosure relating to the estimated cash and investments in market securities of Nektar Therapeutics, a Delaware corporation
(the “Company”), set forth under Item 8.01 “Other Events” of this Current Report on Form 8-K, which is
incorporated by reference into this Item 2.02.
On
January 3, 2018, the Company announced that President and Chief Executive Officer, Howard W. Robin, will make a presentation at
the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2018, at 11:00 a.m. Pacific
Time. The presentation will be accessible via a Webcast through a link posted on the Investors, Investor Events section of
the Nektar website: http://www.nektar.com. In addition, the Company will webcast the Q&A breakout session immediately following
its presentation at 11:30 a.m. Pacific Time. This Webcast will be available for replay until February 20, 2018.
As
part of the presentation,
Mr. Robin intends to announce that, based upon the Company’s preliminary estimates,
as of December 31, 2017, the Company had cash and investments of $353.2 million. This financial information has been
prepared by and is the responsibility of the Company’s management and has not been audited by the Company’s independent
registered public accounting firm. Accordingly, the Company’s independent registered public accounting firm does not express
an opinion on or provide any other form of assurance with respect to this preliminary data. This financial information is subject
to the completion of the Company’s year-end financial closing procedures, the preparation of the Company’s consolidated
financial statements, and the completion of the audit of the Company’s consolidated financial statements as of and for the
year ended December 31, 2017, and the Company’s actual results may differ from these estimates.
The
Company expects the presentation and Q&A breakout session will include certain forward-looking statements regarding the Company’s
business and proprietary drug candidates. Actual results could differ materially from these forward-looking statements, which are
subject to important risks and uncertainties set forth in the Company’s Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on November 8, 2017. The Company undertakes no obligation to update forward-looking statements, whether
as a result of new information, future events or otherwise.
SIGNATURES
Pursuant to the requirement of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
By:
|
/s/ Mark A. Wilson
|
|
|
|
Mark A. Wilson
|
|
|
|
General Counsel and Secretary
|
|
|
|
|
|
Date: January 9, 2018
|
|
|
|
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Apr 2023 to Apr 2024